Currently there is moderate scientific evidence that show positive effects of drotrecogin alfa on survival in patients with severe sepsis. There is moderate scientific evidence of its cost effectiveness. Results from long-term follow-up on the risks and benefits of treatment have yet to be published. Therefore, it is essential to systematically monitor clinical experiences at the national level.